Russ Lebovitz, MD | PhD

CEO & CoFounder

Russ Lebovitz

Russ Lebovitz, MD | PhD

CEO & CoFounder

Russ Lebovitz

About Russ Lebovitz

Dr. Russ Lebovitz brings in-depth expertise in managing biotech companies in the diagnostics field. His broad experience spans from R&D to early-stage to commercial product launch. 

Dr. Lebovitz has spearheaded global projects for Fortune 100 companies and venture-backed startups. The visionary CEO has forged strategic relationships with pharmaceutical companies and renowned clinicians worldwide.

Before his management career, Russ worked as a senior scientist and research physician for over 15 years.

Over his illustrative career, Dr. Lebovitz served on the faculty of Baylor College of Medicine at the Texas Medical Center in Houston and The Fox Chase Cancer Center in Philadelphia.

A champion for brain health drug development, Russ also works closely with the Alzheimer’s Drug Discovery Foundation (ADDF), playing the role of the principal investigator.

Always eager to collaborate on science, Dr. Russ Lebovitz plays an active part in research projects with the Center for Neurologic Study (CNS), the Michael J. Fox Foundation (MJFF), ALS Association (Golden West Chapter), and several other  Lewy Body Dementia organizations.  

To date, Dr. Russ has appeared on 20+ brain health podcasts, spreading the message of early detection. 

Dr. Lebovitz received his M.D. and Ph.D. degrees from the Washington University School of Medicine.

"Improving the world....
One molecule at a time." - Russ Lebovitz


We have great science, great people, and we’re trying to solve difficult but important problems.

Amprion has developed an incredibly exciting and novel technology that looks at overall brain health. We look at things related to Alzheimer’s and Parkinson’s.

What Amprion’s technology allows people to do is to track, in real-time, how their brain is aging with respect to Alzheimer’s and Parkinson’s. And so, by understanding where you are on the spectrum, you can make changes.

One could make changes from lifestyle; people believe that diet or exercise, other lifestyle changes. On the other hand, we believe that one could manage these diseases and their brain health through the next generation of drugs.

I’m most excited that Amprion offers a way for us to address these terrible, terrible diseases and the way that some people age and that their brains go long before their bodies do.

And we can change this; we can help people manage this. At Amprion, we help people do what we call preventive brain care and quality brain aging.

What we do can change the face of Alzheimer’s and Parkinson’s.

Scroll to Top